Mereo BioPharma (MREO) Operating Leases (2018 - 2024)

Mereo BioPharma (MREO) has 7 years of Operating Leases data on file, last reported at $187000.0 in Q4 2024.

• Operating Leases for Q4 2024 came in at $187000.0, down 79.36% year-over-year; the trailing twelve-month figure through Dec 2024 was $187000.0 (down 79.36% YoY), and the FY2024 annual result was $187000.0, down 79.36% from the prior year.
• Operating Leases declined to $187000.0 in Q4 2024 per MREO's latest filing, from $394000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $2.4 million in Q4 2021 and troughed at $187000.0 in Q4 2024.
• A 5-year average of $1.1 million and a median of $816500.0 in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2020 and 2021: Operating Leases plunged 87.24% in 2020, then soared 54.63% in 2021.
• A 5-year view of Operating Leases shows it stood at $1.5 million in 2020, then soared by 54.63% to $2.4 million in 2021, then slipped by 16.26% to $2.0 million in 2022, then sank by 54.24% to $906000.0 in 2023, then slumped by 79.36% to $187000.0 in 2024.
• Business Quant data shows MREO's Operating Leases at $187000.0 in Q4 2024, $394000.0 in Q3 2024, and $552000.0 in Q2 2024.